It should be underlined that the idea to share with patients with EGFR-mutated resected NSCLC the possibility of being administered adjuvant chemotherapy before osimertinib only if “young” and “fit” and not if “elderly” and or “with relevant comorbidities” cannot be considered as completely evidence-based, but may be a “good-sense” decision based on a global view of all the above-mentioned data. Here, EGFR is linked to non-small cell lung carcinoma.